Magnetic Prussian blue nanoparticles for targeted photothermal therapy under magnetic resonance imaging guidance.

Guanglei Fu,Wei Liu,Yanyan Li,Yushen Jin,Lingdong Jiang,Xiaolong Liang,Shanshan Feng,Zhifei Dai
DOI: https://doi.org/10.1021/bc500279w
IF: 4.7
2014-01-01
Bioconjugate Chemistry
Abstract:This paper reported a core-shell nanotheranostic agent by growing Prussian blue (PB) nanoshells of 3-6 nm around superparamagnetic Fe3O4 nanocores for targeted photothermal therapy of cancer under magnetic resonance imaging (MRI) guidance. Both in vitro and in vivo experiments proved that the Fe3O4@PB core-shell nanoparticles showed significant contrast enhancement for T-2-weighted MRI with the relaxivity value of 58.9 mM(-1).s(-1). Simultaneously, the composite nanoparticles exhibited a high photothermal effect under irradiation of a near-infrared laser due to the strong absorption of PB nanoshells, which led to more than 80% death of HeLa cells with only 0.016 mg.mL(-1) of the nanoparticles with the aid of the magnetic targeting effect. Using tumor-bearing nude mice as the model, the near-infrared laser light ablated the tumor effectively in the presence of the Fe3O4@PB nanopartides and the tumor growth inhibition was evaluated to be 87.2%. Capabilities of MRI, magnetic targeting, and photothermal therapy were thus integrated into a single agent to allow efficient MRI-guided targeted photothermal therapy. Most importantly, both PB and Fe3O4 nanoparticles were already clinically approved drugs, so the Fe3O4@PB nanopartides as a theranostic nanomedicine would be particularly promising for clinical applications in the human body due to the reliable biosafety.
What problem does this paper attempt to address?